Skip to main content
AIM Vaccine Co., Ltd. logo

AIM Vaccine Co., Ltd. — Investor Relations & Filings

Ticker · 6660 HKEX Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6660

About AIM Vaccine Co., Ltd.

https://www.aimbio.com

AIM Vaccine Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for human use. The company's mission is to produce high-quality vaccines to safeguard global health. It holds a leading position among privately-owned vaccine enterprises in its primary market. The core product portfolio includes established vaccines such as Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Inactivated Hepatitis A Vaccine (Human Diploid Cell), and Meningococcal Polysaccharide Vaccine. AIM Vaccine is also a major global supplier of rabies vaccines, committed to leading technological advancements in this area. The company actively expands its pipeline, which features advanced candidates like the 13-valent pneumonia conjugate vaccine and iterative serum-free rabies vaccine, alongside strategic investments in mRNA technology, including an mRNA COVID-19 vaccine candidate.

Recent filings

Filing Released Lang Actions
2025 ANNUAL REPORT
Regulatory Filings
2026-04-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a mandatory monthly return (Form FF301) filed to the Hong Kong Stock Exchange detailing movements in authorised/registered share capital, issued shares, treasury shares, and public float sufficiency for the month ended 31 March 2026. It is a compliance/regulatory submission under the Exchange Listing Rules rather than an earnings release, annual or interim report, shareholder vote result, board change, or capital markets transaction announcement. It does not announce a specific new share issuance or corporate action but provides routine monthly regulatory data. Therefore it falls under the general Regulatory Filings category (RNS).
2026-04-02 English
INSIDE INFORMATION PROPOSED APPLICATION BY THE COMPANY FOR THE A SHARE LISTING ON THE BEIJING STOCK EXCHANGE AND ISSUANCE OF DOMESTIC SHARES UNDER SPECIFIC MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is a corporate announcement by AIM Vaccine Co., Ltd. disclosing the proposed issuance of up to 40,000,000 new domestic shares under a specific mandate and the related application for A share listing on the Beijing Stock Exchange. It details the class, number, price range, subscribers, use of proceeds, listing venues, and board authorizations for the share issuance. This is clearly an announcement of a new share issue / capital change rather than a financial report or earnings release, fitting the “Share Issue/Capital Change” category.
2026-03-30 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is an 'Annual Results Announcement' for AIM Vaccine Co., Ltd. for the year ended 31 December 2025. It contains detailed consolidated financial statements (profit or loss, financial position) and notes to the financial statements. While it is an announcement, it provides substantive financial data and is the primary disclosure of the annual results, fitting the definition of an Earnings Release (ER) or an Interim/Quarterly Report (IR) depending on the scope. Given it covers the full fiscal year and provides audited results, it functions as the primary financial disclosure for the period, which aligns with the Earnings Release (ER) category for initial announcements of financial results. FY 2025
2026-03-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. It does not fit into specific categories like earnings releases or annual reports, and since it is a recurring regulatory filing mandated by the Exchange Listing Rules, it falls under the 'Regulatory Filings' category.
2026-03-03 English
VOLUNTARY ANNOUNCEMENT WORLD'S FIRST SERUM-FREE ITERATIVE RABIES VACCINE SUCCESSFULLY PASSED ON-SITE INSPECTION FOR REGISTRATION
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by AIM Vaccine Co., Ltd. regarding the successful on-site inspection for the registration of their serum-free iterative rabies vaccine. It details business developments, clinical trial results, and market implications. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a regulatory announcement regarding company operations, it falls under the RNS (Regulatory Filings) category.
2026-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.